NVAX Long into final clinical trials
Updated
NVAX has received a total of 2.4b in outside funding (gov't and private) which is one of the largest amounts received by the companies involved in Operation Warp Speed. Published vaccine results which few of the companies have made public show the highest amount of vaccine antibody counts (nytimes.com/2020/09/24/health/covid-19-vaccine-novavax.html) Novavax has also reinvested those funds and has an estimated 2 billion dose capacity by 2021 (ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-manufacturing-agreement-serum). Now entering the last phase of their clinical trails with 10,000 participants in the UK if the trail continues to push forward and publishes promising results expect this to run very hard past the previous ATH of $189
Good trade would be continue to acquire $100-$105 range or enter on breakout above $120 with a Stoploss at $94
Hope for a pull back and enter on the golden pocket of $68-75
Long term this company has positive prospects for NanoFlu as well
This trade is active
Assistance for EW analysis from Butch KillTrigger
Good trade would be continue to acquire $100-$105 range or enter on breakout above $120 with a Stoploss at $94
Hope for a pull back and enter on the golden pocket of $68-75
Long term this company has positive prospects for NanoFlu as well
This trade is active
Assistance for EW analysis from Butch KillTrigger
Note
Trade is still active, did not touch the $75 buy zone but original trade still active from $3.90 entry.TP1 - $189
TP2 - $240
Final - $280
Note
Trade 90% closed at $280; the remaining 10% is a moonshot
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.